To advance in vivo proof-of-concept investigations, initial steps could include isolating endogenously occurring MECOM::ETV6 fusion products from the primary leukemia patient cells, mapping the nucleotide sequences of the breakpoints, characterizing potential functional elements, and generating immortalized cell lines using the chimeric fusion genes. This evidence concerns the gene ETV6 and leukemia.